Scenario | Routine 4vHPV vaccination | Routine 9vHPV vaccination | Routine + catch-up 9vHPV vaccination |
---|---|---|---|
Base case | 975,364 | Weakly dominated | 1,534,493 |
Disease consistent with indication | |||
Cervical disease only | 1,349,813 | Weakly dominated | 1,696,915 |
+ anogenital warts | 1,075,713 | Weakly dominated | 1,615,134 |
+ VaIN & VINa | 1,075,713 | Weakly dominated | 1,615,134 |
+ Other HPV-associated disease | |||
+ Vulvar cancer | 1,072,211 | Weakly dominated | 1,609,922 |
+ Vaginal cancer | 1,064,445 | Weakly dominated | 1,597,465 |
+ Anal cancer | 1,037,847 | Weakly dominated | 1,575,198 |
+ Head/neck cancer | 987,668 | Weakly dominated | 1,540,035 |
+ Penile cancer | 987,282 | Weakly dominated | 1,538,902 |
+ Recurrent respiratory papillomatoses | 975,364 | Weakly dominated | 1,534,493 |
Perfect coverage (i.e., 100% among 12–16 y) | 1,349,381 | Weakly dominated | 2,200,881 |
Higher vaccine coverage (i.e., 80% among 12–16 y) | 1,096,548 | Weakly dominated | 1,757,646 |
Lower vaccine coverage (i.e., 60% among 12–16 y) | 861,404 | Weakly dominated | 1,313,380 |
Lower adherence to the 3-dose series (i.e., 80%) | 777,574 | Weakly dominated | 1,219,281 |
Shorter duration of protection for the vaccine (i.e. 10 years for 1-dose, 20 years for 2 doses, and 30 years for 3 doses) | 1,507,122 | Weakly dominated | 1,887,830 |
Low healthy quality of life weights (i.e., all reduced 20%) | 597,871 | Weakly dominated | 1,009,087 |
High healthy quality of life weights (i.e., all increased 20%, up to 1) | 2,236,971 | Weakly dominated | 3,089,664 |
Low disease quality of life weights (i.e., all set to their low values) | 591,713.32 | Weakly dominated | 1,006,573 |
High disease quality of life weights (i.e., all increased 20%, up to 1) | 874,541.87 | Weakly dominated | 1,360,391 |
Low disease costs (i.e., all reduced by 20%) | 1,096,628.38 | Weakly dominated | 1,660,622 |
High disease costs (i.e., all increased by 20%) | 854,098.76 | Weakly dominated | 1,408,364 |
Lower discount rate per year (0%) | 3840 | Weakly dominated | 6283 |
Higher discount rate per year (3%) | 1,575,569.94 | Weakly dominated | 2,433,779 |
Higher discount rate per year (4%) | 2,444,532 | Weakly dominated | 3,740,011 |
Lower vaccine price (i.e. 9vHPV price decreased 10%) | 975,364 | Weakly dominated | 1,091,729 |
Higher vaccine price (i.e. 9vHPV price increased 10%) | 975,364 | Weakly dominated | 1,977,259 |